DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 1I — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 1I maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 1i is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In 1994, the only treatment path for end-stage dilated cardiomyopathy was cardiac transplantation, but only after all conventional and experimental agents—including beta blockade and vesnarinone—had been tried and failed in NYHA class III patients. The scarcity of donor organs was already recognised as a barrier, and alternative methods such as dynamic cardiomyoplasty, permanent mechanical circulatory assistance, and xenografting were proposed as necessary developments. No survival or response rates were given; the paper was a clinical opinion piece, not a trial.
By 2023, heart failure remained a leading cause of death globally, with a new case diagnosed every 23 seconds in India. Dilated cardiomyopathy is defined as left or biventricular dilatation with impaired function not explained by loading conditions or coronary artery disease. Even after diagnosis, only 25–40% of patients receive guideline-directed medical therapy. The abstract gives no new drug data and no survival figures; it emphasises diagnostic and therapeutic heterogeneity as the main challenge.
A 2025 literature review on traditional Chinese medicine for dilated cardiomyopathy states that conservative drug therapy is standard but often limited by adverse effects such as low blood pressure, making satisfactory prognosis difficult. The review claims that traditional Chinese medicine, with its multi-target and syndrome-differentiation approach, has achieved good therapeutic effects with few adverse reactions. However, the abstract provides no concrete numbers—no response rates, no survival data, no sample sizes—and does not name any specific herbal formula or compound. It calls for more ideas and methods but offers no quantitative evidence of benefit.
What is still missing: prospective randomised controlled trials with adequate sample sizes, standardised outcome measures (survival, ejection fraction, hospitalisation rates), and clear patient stratification by aetiology and disease stage. No drug—whether vesnarinone, beta blockers, or any traditional Chinese medicine—has been shown in these abstracts to alter the natural history of dilated cardiomyopathy in a definitive, reproducible way. Funding for such trials and a trial design that accounts for the heterogeneity of the disease remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Medical Archives · 2018 · 7 citations · open access
Clinical Course and Treatment of Dilated Cardiomyopathy During Twenty Years of Follow-up
AbstractOBJECTIVE: Demonstration of idiopathic dilated cardiomyopathy with unusual flow, unpredictable clinical picture and complex therapy. CASE REPORT: Patient A.P., female, 38 years old, had symptoms of dilated cardiomyopathy (with possible infectious myocarditis in the background) at age 17. After hospitalization for ten months and ten days, while waiting for heart transplantation (with threatening death outcome), without a clearly pronounced threatening arrhythmia, but with a low ejection fraction and a poor general condition, remission occurred. The therapy focused primarily on the treatment of heart failure, prevention of arrhythmia and thromboembolism. Normalization of the disease by improving the function of the left ventricle (expected in 16% of patients) occurred and lasted for 4 years, followed by an exacerbation of the disease that lasted for two years. In the next few years the patient was stable, had a first child with normal pregnancy. During the second trimester of the second pregnancy, there was an exacerbation (postpartum dilatation cardiomyopathy) lasting for couple of months. At the time of case report (May 2017), the patient is stable on therapy (ACE inhibitor, beta blocker, diuretics, If channel blocker), without limitation of physical capacity, mother of two children, unemployed. CONCLUSION: The clinical course of dilated cardiomyopathy is extremely unpredictable and therapy is very complex and demanding.
AbstractPatients should be referred for cardiac transplantation only after all other means of management of congestive heart failure have been attempted and have been unsuccessful (table 3). An adequate therapeutic trial of conventional and experimental agents including beta blockade and vesnarinone should be completed and be shown to be unsuccessful before transplantation is considered in patients in NYHA class III. Prospective clinical trials need to be completed to define the role of newer therapeutic options. The scarcity of donor organs will probably preclude the use of cardiac transplantation in all patients who may benefit. Alternative methods of cardiac replacement (such as dynamic cardiomyoplasty, permanent implantable mechanical circulatory assistance, and xenografting) must be developed. These methods coupled with better pharmacological treatment will greatly improve the outcome of patients with dilated cardiomyopathy.
Heart failure journal of India · 2023 · 0 citations · open access
Management of non-ischemic dilated cardiomyopathy
AbstractHeart failure (HF) remains a leading cause of morbidity and mortality globally. For every 23 s, a new case of HF is diagnosed in India. Dilated cardiomyopathy is characterized by dilatation of the left ventricle or both ventricles with impaired function, which cannot be fully explained by abnormal loading conditions or coronary artery disease. The heterogeneity in etiology and clinical presentation of dilated cardiomyopathy makes timely diagnosis and treatment challenging. Even after diagnosis, only 25%–40% receive guideline-directed medical therapy.
International Journal of General Medicine · 2025 · 0 citations · open access
Traditional Chinese Medicine Treating Dilated Cardiomyopathy: A Literature Review
AbstractDilated cardiomyopathy (DCM), as a difficult problem in modern medical treatment, has become an important cardiovascular disease threatening human beings all over the world with an increasing incidence rate and mortality. Conservative drug therapy is mainly used in clinical practice, but due to unavoidable adverse reactions such as low blood pressure, it is often difficult to achieve satisfactory prognosis. Traditional Chinese medicine has the characteristics of syndrome differentiation and multi-target treatment for DCM, with few adverse reactions and certain advantages. It has achieved good therapeutic effects in clinical practice. Therefore, we summarized and analyzed the clinical evidence and mechanism of traditional Chinese medicine in the treatment of DCM, and combined with the current research status of this disease to analyze the problems and shortcomings, in order to provide more ideas and methods for the treatment of DCM with traditional Chinese medicine.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
